Cargando…
Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value
The identification of predictive factors for treatment of pancreatic cancer (PC) is an unmet clinical need. In the present work, we analyzed blood-derived extracellular vesicles (EVs) from patients with advanced PC in order to find a molecular signature predictive of response to therapy. We analyzed...
Autores principales: | Vannini, Ivan, Rossi, Tania, Melloni, Mattia, Valgiusti, Martina, Urbini, Milena, Passardi, Alessandro, Bartolini, Giulia, Gallio, Chiara, Azzali, Irene, Bandini, Sara, Ancarani, Valentina, Montanaro, Lorenzo, Frassineti, Giovanni Luca, Fabbri, Francesco, Rapposelli, Ilario Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238807/ https://www.ncbi.nlm.nih.gov/pubmed/37273899 http://dx.doi.org/10.1016/j.omtm.2023.05.009 |
Ejemplares similares
-
Case Report: Analysis of Plasma Extracellular Vesicles in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient
por: Vannini, Ivan, et al.
Publicado: (2022) -
Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021) -
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021) -
Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies
por: Passardi, Alessandro, et al.
Publicado: (2021) -
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer
por: Marisi, Giorgia, et al.
Publicado: (2023)